NSTEMI Timing and Management

 NSTEMI Timing and Management

---

Introduction

Non–ST Elevation Myocardial Infarction (NSTEMI) is a common form of Acute Coronary Syndrome (ACS) characterized by myocardial necrosis without persistent ST-segment elevation on ECG. It results from partial or transient occlusion of a coronary artery and requires rapid risk stratification and timely management to prevent progression to larger infarction or death.

Early recognition and appropriate timing of invasive management are critical components of modern NSTEMI care.

---

Pathophysiology

NSTEMI usually occurs due to rupture or erosion of an atherosclerotic plaque followed by platelet aggregation and thrombus formation. Unlike STEMI, the occlusion is often incomplete or intermittent, leading to subendocardial ischemia rather than full-thickness myocardial infarction.

Key mechanisms include:

• Plaque rupture with non-occlusive thrombus

• Severe coronary artery stenosis

• Coronary vasospasm

• Supply–demand mismatch in vulnerable myocardium

This results in myocardial injury with elevation of cardiac biomarkers such as troponin.

---

Clinical Presentation

Patients with NSTEMI commonly present with symptoms similar to other acute coronary syndromes.

Typical features include:

• Chest pain or pressure lasting >20 minutes

• Radiation to arm, jaw, or back

• Dyspnea

• Diaphoresis

• Nausea or vomiting

High-risk patients such as elderly individuals, diabetics, and women may present atypically.

---

Diagnostic Criteria

Diagnosis of NSTEMI requires evidence of myocardial injury along with clinical or ECG evidence of ischemia.

Key diagnostic components include:

1. Cardiac Biomarkers

Elevated high-sensitivity troponin with a rising or falling pattern.

2. ECG Findings

ECG may show:

• ST-segment depression

• T-wave inversion

• Transient ST elevation

• Sometimes normal ECG

3. Clinical Context

Ischemic symptoms or imaging evidence of myocardial ischemia.

---

Initial Emergency Management

Immediate treatment focuses on stabilizing the patient and preventing further thrombus formation.

Core therapies include:

Antiplatelet Therapy

• Aspirin loading dose (150–325 mg)

• P2Y12 inhibitor (Clopidogrel, Ticagrelor, or Prasugrel)

Anticoagulation

• Unfractionated heparin

• Enoxaparin

• Bivalirudin (during PCI)

Anti-Ischemic Therapy

• Nitroglycerin

• Beta blockers

• Statins (high-intensity)

Other supportive treatments

• Oxygen if saturation <90%

• Pain control

• Hemodynamic stabilization

---

Risk Stratification

Risk assessment guides the timing of invasive management.

Important risk scoring systems include:

GRACE Score

Predicts mortality and guides invasive strategy timing.

TIMI Score

Assesses risk of death and ischemic events.

High-risk features include:

• Elevated troponin

• Dynamic ST changes

• Hemodynamic instability

• Ventricular arrhythmias

• Heart failure

---

Timing of Invasive Management

Current ESC and ACC/AHA guidelines recommend different invasive strategies depending on risk profile.

---

Immediate Invasive Strategy (<2 hours)

Urgent coronary angiography is recommended in patients with very high-risk features.

Indications include:

• Hemodynamic instability or cardiogenic shock

• Refractory chest pain

• Life-threatening arrhythmias

• Mechanical complications

• Acute heart failure with ischemia

These patients should be treated similar to STEMI with emergency revascularization.

---

Early Invasive Strategy (<24 hours)

Recommended for high-risk NSTEMI patients.

Criteria include:

• GRACE score >140

• Dynamic ST-segment depression or elevation

• Elevated troponin indicating myocardial injury

Early coronary angiography within 24 hours improves outcomes and reduces recurrent ischemia.

---

Delayed Invasive Strategy (<72 hours)

Appropriate for intermediate-risk patients.

Features include:

• Diabetes mellitus

• Reduced ejection fraction (<40%)

• Prior PCI or CABG

• Renal dysfunction

• Early post-infarction angina

These patients benefit from angiography within 72 hours.

---

Conservative Strategy

A selective invasive approach can be considered in low-risk patients.

Criteria include:

• Negative troponin

• No ischemic ECG changes

• Low risk scores

These patients undergo non-invasive ischemia testing before discharge.

---

Revascularization Options

After coronary angiography, revascularization depends on coronary anatomy.

Percutaneous Coronary Intervention (PCI)

Most NSTEMI patients undergo PCI with drug-eluting stent placement.

Coronary Artery Bypass Grafting (CABG)

Preferred in:

• Left main disease

• Complex multivessel disease

• Diabetic patients with diffuse CAD

---

Secondary Prevention

Long-term therapy is essential to prevent recurrent events.

Recommended treatments include:

Dual Antiplatelet Therapy (DAPT)

• Aspirin + P2Y12 inhibitor for 12 months

High-Intensity Statins

• Atorvastatin or Rosuvastatin

ACE Inhibitors / ARBs

Particularly in patients with LV dysfunction or diabetes.

Beta Blockers

Reduce myocardial oxygen demand and arrhythmia risk.

Lifestyle Modifications

• Smoking cessation

• Weight control

• Regular exercise

• Blood pressure and diabetes control

---

Prognosis

NSTEMI patients have lower early mortality compared with STEMI but a similar or higher long-term risk of recurrent cardiovascular events.

Early invasive management combined with optimal medical therapy significantly improves survival and reduces complications.

---

Key Takeaways

• NSTEMI results from partial coronary occlusion leading to myocardial injury without ST elevation.

• Diagnosis requires elevated troponin with ischemic symptoms or ECG changes.

• Risk stratification using GRACE or TIMI scores guides management strategy.

• Immediate angiography (<2 hours) is required in unstable patients.

• Early invasive strategy (<24 hours) is recommended for high-risk NSTEMI.

• Intermediate-risk patients undergo angiography within 72 hours.

• Long-term secondary prevention with DAPT, statins, and lifestyle changes is essential.

---

drmusmanjaved.com